Genfit (GNFT)

3.25
-0.05(-1.57%)
  • Volume:
    73,213
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    3.17 - 3.29
  • Type:Equity
  • Market:France
  • ISIN:FR0004163111

GNFT Overview

Prev. Close
3.3
Day's Range
3.17-3.29
Revenue
85.58M
Open
3.17
52 wk Range
2.75-4.95
EPS
1.07
Volume
73,213
Market Cap
159.54M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
118,671
P/E Ratio
3.09
Beta
1.13
1-Year Change
-1.04%
Shares Outstanding
49,678,477
Next Earnings Date
Sep 28, 2022
What is your sentiment on Genfit?
or
Market is currently closed. Voting is open during market hours.

Genfit News

Genfit Analysis

Genfit Company Profile

Genfit Company Profile

Employees
122
Market
France

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company’s products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellSellStrong SellBuyStrong Sell
SummaryStrong SellStrong SellStrong SellNeutralStrong Sell
  • what's the reason of fall of Genfit?
    0
    • i also want to know
      0
    • dont worry it Will raise soon 😉
      1
  • it cheap to buy
    0
    • Trials for NASH will continue after dataset correction
      2
      • they failed the drug test and NASH drug was the only viable drug that they were developing , so practically they lost almost all value with that failure...
        1
        • not all value but a drug development. they have so many programs to continue
          0
      • damn what was wrong w this beast? from 2x all the way down to 5 w low volume?
        0
        • Whats the status , will it still go down ?
          0
          • Yes
            0
        • this baby Is the brother of contravirpharma (HEPA) .. same diseases.
          0
          • what do you mean?
            0
        • WHAT IS THE BEST STOCK TO BUY TODAY ??/ ANT RECOMMENDATION
          0
          • does anyone have an explaination for the sudden fall same day of the Nasdaq trading?
            0
            • Mathieu Gandrille ah you mean to buy because it would be oversold
              0
            • MfB Iod  i mean if 5 i would buy, and sell at 8
              0
            • Mathieu Gandrille are you a KOL?
              0
          • DATA is opn in 1Q 2019?
            0